Immunetic Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 23-10-2024
- Paid Up Capital ₹ 4.91 Cr
as on 23-10-2024
- Company Age 16 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 21.04 Cr
as on 23-10-2024
- Satisfied Charges ₹ 4.24 Cr
as on 23-10-2024
- Revenue 14.45%
(FY 2023)
- Profit 30.40%
(FY 2023)
- Ebitda 16.20%
(FY 2023)
- Net Worth 22.60%
(FY 2023)
- Total Assets 7.89%
(FY 2023)
About Immunetic Lifesciences
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 4.91 Cr.
The company currently has active open charges totaling ₹21.04 Cr. The company has closed loans amounting to ₹4.24 Cr, as per Ministry of Corporate Affairs (MCA) records.
Rahul Kapur, Vinod Kapur, and Deepak Kapur serve as directors at the Company.
- CIN/LLPIN
U29297DL2008PTC182062
- Company No.
182062
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Aug 2008
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Immunetic Lifesciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rahul Kapur  | Director | 14-Aug-2008 | Current |
| Deepak Kapur | Director | 14-Aug-2008 | Current |
| Vinod Kapur | Director | 07-Aug-2017 | Current |
Financial Performance of Immunetic Lifesciences.
Immunetic Lifesciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 14.45% increase. The company also saw a substantial improvement in profitability, with a 30.4% increase in profit. The company's net worth Soared by an impressive increase of 22.6%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Immunetic Lifesciences?
In 2023, Immunetic Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Indovax Private LimitedActive 38 years 6 monthsRahul Kapur, Vinod Kapur and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 15 Mar 2023 | ₹6.10 Cr | Open |
Others Creation Date: 27 Dec 2017 | ₹14.94 Cr | Open |
Idbi Bank Limited Creation Date: 19 Jul 2011 | ₹4.24 Cr | Satisfied |
How Many Employees Work at Immunetic Lifesciences?
Immunetic Lifesciences has a workforce of 40 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Immunetic Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Immunetic Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
